glp-1 obesity drug news today 2025 Alarming rise in weight loss overdoses The Trump administration is preparing

In addition to todays resource, please see and review the New York Times article, The Risks of Taking Drugs Like Ozempic When Youre Over 65: Medications that cause drastic weight loss raise specific concerns for older adults

no major safety concerns were observed

Understand about the investigational Alluvi Retatrutide 40 mg injection a GLP-1 + GIP + Glucagon triple-agonist studied for obesity

The fascinating history of the GLP-1 drugs- Ozempic, Wegovy, and Mounjaro.

Do not reuse

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence